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Abstract: Irritable bowel syndrome (IBS) is a common gastrointestinal (GI) disorder charac-
terized by abdominal pain that occurs with defecation or alterations in bowel habits. Further 
classification is based on the predominant bowel habit: constipation-predominant IBS, diarrhea-
predominant IBS (IBS-D), or mixed IBS. The pathogenesis of IBS is unclear and is considered 
multifactorial in nature. GI dysbiosis, thought to play a role in IBS pathophysiology, has been 
observed in patients with IBS. Alterations in the gut microbiota are observed in patients with 
small intestinal bacterial overgrowth, and overgrowth may occur in a subset of patients with IBS. 
The management of IBS includes therapies targeting the putative factors involved in the patho-
genesis of the condition. However, many of these interventions (eg, eluxadoline and alosetron) 
require long-term, daily administration and have important safety considerations. Agents thought 
to modulate the gut microbiota (eg, antibiotics and probiotics) have shown potential benefits in 
clinical studies. However, conventional antibiotics (eg, neomycin) are associated with several 
adverse events and/or the risk of bacterial antibiotic resistance, and probiotics lack uniformity 
in composition and consistency of response in patients. Rifaximin, a nonsystemic antibiotic 
administered as a 2-week course of therapy, has been shown to be safe and efficacious for the 
treatment of IBS-D. Rifaximin exhibits a favorable benefit-to-harm ratio when compared with 
daily therapies for IBS-D (eg, alosetron and tricyclic antidepressants), and rifaximin was not 
associated with the emergence of bacterial antibiotic resistance. Thus, short-course therapy with 
rifaximin is an appropriate treatment option for IBS-D.
Keywords: antibiotic, diarrhea, dysbiosis, gastrointestinal, pain, Xifaxan
Introduction
Irritable bowel syndrome (IBS) is a chronic gastrointestinal (GI) disorder characterized 
by recurring abdominal pain associated with evacuation or changes in bowel habits 
(ie, stool form and stool frequency).1 IBS is commonly subclassified based on the 
predominant bowel habit (ie, constipation-predominant IBS, diarrhea-predominant 
IBS [IBS-D], or mixed IBS [an occurrence of both constipation and diarrhea]). A 
common disorder, IBS is estimated to affect ~11% of adults worldwide.2,3 The patho-
genesis of IBS is not completely understood, but is considered multifactorial, with the 
immune system, gut–brain axis, and gut microbiota thought to play roles.4–7 Indeed, 
increased concentrations of proinflammatory cytokines (ie, interleukin-6 and tumor 
necrosis factor-α) have been observed in patients with IBS compared with healthy 
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individuals.5 Further, interactions between the gut microbiota 
and central nervous system (ie, gut–brain axis) are thought to 
play a role in IBS pathogenesis, and the interaction is likely 
bidirectional. For example, psychiatric comorbidities (eg, 
anxiety and depression) are common in patients with IBS.6 
Abdominal pain, a key component of the clinical definition 
of IBS, is one of the most common symptoms resulting in 
patients with IBS seeking consultation with a health care 
provider.8 The management of IBS is based on specific GI 
symptoms (eg, diarrhea and constipation) and the sever-
ity of those symptoms.1 However, patients with IBS may 
experience variations in predominant symptoms and/or IBS 
subtypes during their lifetime, necessitating adjustments in 
management approaches.9
IBS has a substantial negative effect on patients. Data 
suggest that patients with IBS-D experience significantly 
greater decreases in health-related quality of life and 
increased impairment of daily activities compared with 
healthy individuals (p<0.001 for both comparisons).3 In 
addition, work absenteeism (ie, the percentage of work time 
missed related to health issues) and presenteeism (ie, the 
percentage of impairment experienced during work time 
related to health issues) are significantly more common in 
patients with IBS-D than in healthy individuals (absentee-
ism, 5.1% vs 2.9%, respectively; p=0.004; presenteeism, 
17.9% vs 11.3%; p<0.001).3
The aim of the current article was to provide an overview 
of the role of short-course therapy with rifaximin in the 
management of patients with IBS-D.
Materials and methods
A PubMed search of English language articles available 
through May 9, 2017, was conducted using the following 
keywords to identify relevant articles and studies performed 
in adult humans: “irritable bowel syndrome,” “pathogenesis 
OR pathophysiology,” “gut dysbiosis OR microbiota,” “small 
intestinal bacterial overgrowth,” “breath testing,” “treatment,” 
“management,” “antibiotic,” and “rifaximin.”
Role of gut microbiota in IBS
Intestinal dysbiosis, or alterations in the quantity or com-
position of GI-associated microbiota, has been observed 
in patients with IBS.10–14 For example, results of a meta-
analysis demonstrated that the expression of Lactobacillus 
and Bifidobacterium differed significantly between patients 
with IBS-D and healthy individuals (p=0.02 and p=0.001, 
respectively).7 In addition, patients with IBS-D appear to 
have significantly lower concentrations of aerobic bacteria 
than that of healthy individuals (1.4×107 vs 8.4×108 colony-
forming units [CFUs]/g feces, respectively; p=0.002).10
In a longitudinal study, gut microbial instability (ie, differ-
ences in microbial numbers or composition; determined using 
culture-independent molecular analysis [ie, PCR-denaturing 
gradient gel electrophoresis]) was greater in patients with IBS 
than in healthy individuals during a 6-month period (43% 
vs 29%, respectively).15 This greater instability (ie, temporal 
changes) in the gut microbial composition versus healthy 
individuals has also been specifically shown in patients with 
IBS-D.13,16,17 In addition, when the gut microbiota of a pooled 
IBS subtype population was analyzed by IBS symptom sever-
ity, patients with severe IBS (defined as IBS severity score 
>300, maximum score of 500) had decreased microbial diver-
sity, increased Bacteroides, and a lack of Methanobacteriales 
compared with the gut microbiota of healthy individuals.18 
To date, studies comparing the gut microbiota of patients 
with IBS with that of healthy individuals have been limited 
to demonstrating an association between dysbiosis and IBS; 
cause and effect remain to be elucidated.19
Small intestinal bacterial overgrowth (SIBO), character-
ized by quantitative and qualitative alterations in bacteria in 
the small intestine, is a diagnosis that may be considered in 
patients with nonspecific symptoms of abdominal pain, bloat-
ing, and diarrhea.20,21 Further, patients who use proton pump 
inhibitors (PPIs) may be at a greater risk of developing SIBO, 
as findings of a meta-analysis of 19 studies reported that PPIs 
significantly increased the risk of SIBO (odds ratio [OR], 1.7; 
95% confidence interval [CI], 1.2–2.4).22 However, a study 
of patients undergoing upper GI tract endoscopy (n=897) 
showed no association between PPI use and SIBO.23 In 2017, 
the North American Consensus group on hydrogen- and 
methane-based breath testing proposed a bacterial concentra-
tion of >103 CFU/mL following aspiration of small intestine 
fluid and subsequent culture as meeting the threshold for a 
diagnosis of SIBO.24 In one study, more patients with IBS 
(43%) achieved a positive culture threshold of ≥5×103 CFU/
mL compared with healthy individuals (12%; p=0.002).25 
Conversely, a retrospective study of patients with IBS failed 
to show an association between IBS and SIBO (OR, 0.2; 95% 
CI, 0.1–0.7).26 However, obtaining small intestinal aspirate 
samples for culture is an invasive procedure, and differences 
in findings may be related to inconsistencies in sample col-
lection, in vitro growth, and the potential for contamination 
(ie, bacteria from outside the small intestine).24,27
Although criteria for diagnosing IBS are based on 
patient symptoms, breath testing – a method that measures 
the production of gases (eg, hydrogen and methane) that 
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result from bacterial fermentation of orally administered 
but unabsorbed carbohydrates (eg, glucose, lactose, and 
lactulose) in the GI tract – may be used for various reasons, 
such as to determine the presence of SIBO or carbohydrate 
malabsorption.1,24,28 A meta-analysis of 11 studies found that 
positive breath tests occurred more frequently in patients 
with IBS (n=1076) than in healthy individuals (n=509; OR, 
4.5; 95% CI, 1.7–11.8; p=0.003).29 A study published after 
that meta-analysis was conducted reported that 23.7% of 
patients with IBS had positive breath test results compared 
with 2.7% of healthy individuals (p=0.008).30 That study also 
reported that, based on breath test results, SIBO was more 
prevalent in patients with IBS-D (37.0%) than in patients 
with other IBS subtypes (12.5%; p=0.02).30 However, other 
studies have failed to demonstrate an association between 
SIBO (based on breath testing) and IBS.31,32 Thus, bacterial 
culture and breath-testing data appear to suggest that at least 
a subset of patients with IBS may have alterations in their gut 
microbiota. These findings, which remain to be confirmed 
by larger, well-designed studies, suggest that empiric treat-
ment of patients with IBS thought to have comorbid SIBO 
may be warranted.9,29,33
Given the multifactorial nature of IBS, various types of 
therapeutic options are prescribed to help manage the symp-
toms of IBS-D (Table 1).1 To manage individual symptoms of 
IBS, most of these agents must be administered daily, either 
long term or as needed (eg, antispasmodics or peppermint 
oil for abdominal pain), or administered off-label to manage 
global IBS symptoms alongside psychiatric comorbidities 
(eg, tricyclic antidepressants or selective serotonin reuptake 
inhibitors may improve coexisting anxiety or depression, as 
well as decrease visceral pain).9
Some agents (eg, antibiotics and probiotics) administered 
for the treatment of IBS are thought to modulate the gut 
microbiota, possibly by correcting dysbiosis.1,12–14 Patients 
with IBS treated with short-course conventional (traditional) 
antibiotics (ie, ciprofloxacin, doxycycline, neomycin, and 
metronidazole) have had improvements in IBS symptoms, 
such as diarrhea (p<0.05) and abdominal pain (p<0.001).34 
Results of a double-blind, randomized, placebo-controlled 
study demonstrated that patients with IBS receiving neomy-
cin had a significantly greater decrease in the IBS composite 
symptom score (ie, abdominal pain, diarrhea, and constipa-
tion) compared with placebo (35.0% vs 11.4%, respectively; 
p<0.05); neomycin was more likely to result in a clinical 
response (ie, ≥50% improvement from baseline in composite 
symptom score) than placebo (44% vs 23%; OR, 4.3; CI, 
1.0–6.3; p<0.05).35 Further, a retrospective chart review of 
patients with IBS and the presence of methane by lactulose 
breath testing showed that neomycin was associated with 
clinical response in 63% of 8 patients.36 However, the use 
of these conventional antibiotics is limited by the risk for 
Clostridium difficile infection, the potential for the emergence 
of bacterial antibiotic resistance, and the risk of systemic 
adverse events (AEs) such as ototoxicity (ie, neomycin).37–39 
These agents should be avoided in routine clinical practice 
for the treatment of IBS. Further, some patients with IBS 
may not respond to retreatment with conventional antibiotics 
when IBS symptoms recur.38,40
In general, probiotics, typically administered daily, may 
improve global symptoms of IBS, along with bloating and 
flatulence.9 Interestingly, data for a subset of studies in a 
2016 meta-analysis (13 trials; n=889 patients) indicated that 
probiotics do not improve abdominal pain, a key individual 
symptom in IBS, versus placebo.41 Furthermore, there is a 
lack of consistency of response in patients (Table 2),41–46 
likely because probiotic formulations vary in composition 
(single or multiple species and strains of microbes) and 
dose and duration and also because the trials conducted have 
often been considered substandard.9,41 Moreover, results with 
one strain cannot be extrapolated to another strain from the 
Table 1 Therapies for the management of patients with IBS-D
Therapeutic class Example of therapy Dosing
Antibiotics Rifaximin 550 mg tid for 
14 days
Antispasmodics Dicyclomine
Hyoscyamine
10–20 mg qd–qid
0.125–0.25 mg every 
4 hours as needed
Bile acid sequestrants Cholestyramine
Colesevelam
Colestipol
9 g bid–tid
625 mg qd–bid
2 g qd–bid
Diet Low gluten/gluten-free
Low FODMAP
Daily
Daily
Mixed opioid agonist/
antagonist
Eluxadoline 100 mg bid
Opioid agonists Loperamide 2–4 mg as needed; 
titrated to 16 mg/d
Peppermint oil Enteric-coated capsules 250–750 mg bid–tid
Probiotics Multiple products Daily
Selective serotonin 
reuptake inhibitors
Citalopram
Paroxetine
Sertraline
10–40 mg qd
10–40 mg qd
25–100 mg qd
Tricyclic antidepressants Amitriptyline
Desipramine
10–50 mg qhs
25–100 mg qhs
5-HT3 antagonists Alosetron
Ondansetrona
0.5–1 mg bid 
(women only)
4–8 mg tid
Note: aNot indicated for use in patients with IBS. Adapted from Gastroenterology, 
150(6), Lacy BE, Mearin F, Chang L, et al, Bowel disorders, 1393–1407, Copyright 
(2016), with permission from Elsevier.1
Abbreviations: 5-HT3, serotonin; bid, twice daily; FODMAP, fermentable 
oligosaccharides, disaccharides, monosaccharides, and polyols; IBS, irritable bowel 
syndrome; IBS-D, diarrhea-predominant irritable bowel syndrome; qd, once daily; 
qhs, nightly at bedtime; qid, four times daily; tid, three times daily.
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Table 2 Summary of meta-analyses of randomized, controlled studies of antibiotics and probiotics in patients with IBS
Publication Patient inclusion criteria RCTs in 
meta‑analysis, n
Outcomes
Antibiotics
Li et al42 •	 Adults aged ≥18 years
•	 IBS diagnosis
4 (n=1803 pts) •	 Remission of overall IBS symptoms, rifaximin vs placebo
−	 End of treatment: OR, 1.2 (95% CI, 1.1–1.3; p=0.0008)
−	 End of follow-up: OR, 1.4 (95% CI, 1.2–1.6; p<0.0001)
•	 Adverse events, rifaximin vs placebo
−	 Abdominal pain (n=3 studies): OR, 1.01 (95% CI, 0.98–1.03; p=0.6)
−	 Nausea (n=3 studies): OR, 1.0 (95% CI, 0.98–1.02; p=0.8)
−	 Vomiting (n=3 studies): OR, 0.99 (95% CI, 0.98–1.01; p=0.3)
−	 Headache (n=3 studies): OR, 1.01 (95% CI, 0.98–1.03; p=0.6)
Menees 
et al43
•	 IBS diagnosis (according 
to Manning, Kruis, Rome I, 
Rome II, Rome III criteria)
5 (n=1803 pts) •	 Improvement of global IBS symptoms, rifaximin vs placebo
−	 42.2% vs 32.4%; OR, 1.6 (95% CI, 1.2–2.0; p<0.001)
•	 Improvement in bloatinga, rifaximin vs placebo (n=4 studies)
−	 41.6% vs 31.7%; OR, 1.6 (95% CI, 1.2–2.0; p<0.001)
Probiotics
Zhang et al41 •	 IBS diagnosis (Rome III 
criteria)
•	 Treatment ≥7 days
Overall: 21 •	 Overall symptom response (n=16 studies; n=1275 pts)
−	 Probiotics vs placebo: 53.3% vs 27.7% (RR, 1.8; 95% CI, 1.3–2.6)
•	 Abdominal pain response (n=13 studies; n=889)
−	 Probiotics vs placebo: SMD, −0.3 (95% CI, −0.6 to 0.1)
•	 Bloating (n=13 studies; n=890 pts)
−	 Probiotics vs placebo: SMD, −0.2 (95% CI, −0.5 to 0.1)
•	 QOL (n=9 studies; n=629 pts)
−	 Probiotics vs placebo: SMD=0.3 (95% CI, 0.1–0.5)
Didari 
et al44,b
•	 IBS diagnosis (Rome II and 
III criteria, and International 
Classification of Health 
Problems in Primary Care 
and World Organization of 
Family Doctors)
Overall: 15 (n=1793 pts) •	 Global symptom response (n=2 studies)
−	 Probiotics vs placebo: RR, 2.4 (95% CI, 1.1–5.2; p=0.02)
•	 Adequate general symptoms improvement (n=6 studies)
−	 Probiotics vs placebo: RR, 2.1 (95% CI, 1.1–4.3; p=0.03)
•	 Abdominal pain response (n=2 studies)
−	 Probiotics vs placebo: RR, 2.0 (95% CI, 1.1–3.4; p=0.01)
Ford et al45 •	 Adults aged >16 years with 
IBS
•	 Treatment ≥7 days
•	 Follow-up ≥7 days
•	 Overall: 35
−	 Combination 
probiotics: 19
−	 Lactobacillus: 8
−	 Bifidobacterium: 3
−	 Escherichia: 2
−	 Bifidobacterium or 
Lactobacillus: 1
−	 Saccharomyces: 1
−	 Streptococcus: 1
•	 Persistent or unimproved symptoms (n=23 studies; n=2575 pts)
−	 Probiotics vs placebo: 55.8% vs 73.1% (RR, 0.8; 95% CI, 0.7–0.9)
•	 Global IBS or abdominal pain scores (n=24 studies; n=2026 pts)
−	 SMD=−0.3 (95% CI, −0.4 to −0.1)
•	 Bloating (n=17 studies; n=1446 pts)
−	 SMD=−0.2 (95% CI, −0.3 to −0.03)
•	 Flatulence (n=10 studies; n=741 pts)
−	 SMD=−0.2 (95% CI, −0.4 to −0.07)
•	 Urgency (n=6 studies; n=635 pts)
−	 SMD=−0.1 (95% CI, −0.3 to 0.1)
•	 Adverse events (n=24 studies; n=2407 pts)
−	 Probiotics vs placebo: 16.5% vs 13.8% (RR, 1.2; 95% CI, 1.02–1.4)
Moayyedi 
et al46
•	 Adults aged >16 y with IBS
•	 Treatment ≥7 days
•	 Follow-up ≥7 days
•	 Overall: 18
−	 Combination 
probiotics: 9
−	 Lactobacillus: 6
−	 Bifidobacterium: 3
−	 Lactobacillus and 
Bifidobacterium: 1
−	 Streptococcus: 1
•	 Overall symptom response (n=15 studies; n=1351 pts)
−	 Probiotics vs placebo: SMD=−0.3 (95% CI, −0.6 to −0.07)
•	 Persistent or unimproved overall symptoms (n=10 studies; n=918 pts)
−	 Probiotics vs placebo: RR, 0.7 (95% CI, 0.6–0.9)
•	 Abdominal pain response (n=9 studies; n=834 pts)
−	 Probiotics vs placebo: SMD=−0.5 (95% CI, −0.9 to −0.1; p=0.02)
•	 Bloating (n=7 studies; n=682 pts)
−	 Probiotics vs placebo: SMD=−0.5 (95% CI, −1.1 to 0.02; p=0.06)
•	 Flatulence (n=6 studies; n=566 pts)
−	 Probiotics vs placebo: SMD=−0.2 (95% CI, −0.4 to −0.01; p=0.04)
•	 Urgency (n=3 studies; n=394 pts)
−	 Probiotics vs placebo: SMD=−0.1 (95% CI, −0.3 to 0.1; p=0.5)
•	 Adverse events (n=3 studies; n=407 pts)
−	 Probiotics vs placebo: RR, 0.9 (95% CI, 0.6–1.4)
Notes: aAt 10–14 days after treatment;43 bnumber of patients not reported for individual outcomes. Data from references 41–46.
Abbreviations: CI, confidence interval; IBS, irritable bowel syndrome; OR, odds ratio; QOL, quality of life; pts, patients; RCT, randomized controlled trial; RR, relative 
risk; SMD, standard mean difference.
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same species.9 However, an open-label, prospective study 
published in 2018 demonstrated that 30-day treatment with 
a commercially available probiotic significantly improved 
bowel function satisfaction in patients with IBS-D (n=11) 
compared with patients with non-IBS-D (n=15) on days 30 
and 60 (p=0.05 and 0.04, respectively).47 Further, following 
30-day probiotic treatment, patients with IBS and concomi-
tant SIBO experienced a significantly greater decrease from 
baseline in the severity of IBS symptoms compared with 
patients with IBS without SIBO at day 60 (71.3% vs 10.6%, 
respectively; p=0.02).47 Given the potential benefit in target-
ing the gut microbiota, a nonsystemic antibiotic has been 
investigated to prevent the need for long-term daily therapy 
and minimize possible AEs.
Rifaximin for the treatment of IBS
Rifaximin, a nonsystemic antibiotic indicated in the USA 
for the treatment of adults with IBS-D, is administered as 
a 2-week course of therapy.48 Rifaximin is also indicated 
as a daily therapy for the reduction of risk of overt hepatic 
encephalopathy in adults.48 The mechanism of action of 
rifaximin, including in IBS, is not fully understood. How-
ever, its activities for the treatment of various GI-related 
conditions are thought to involve modulation of the gut 
microbiota (eg, SIBO eradication),49 immune components 
(eg, decreased proinflammatory cytokine concentrations),50 
and the gut–brain axis (eg, cognitive improvement observed 
in patients with cirrhosis).51 Rifaximin has been evaluated 
in three phase III IBS trials,52,53 and findings of randomized, 
placebo-controlled trials of rifaximin have been summarized 
in several meta-analyses (Table 2).42,43 In two phase III, identi-
cally designed, randomized, double-blind, placebo-controlled 
studies, significantly more patients receiving rifaximin 550 
mg three times daily (tid) for 2 weeks achieved adequate 
relief from global IBS symptoms for ≥2 of the first 4 weeks 
posttreatment compared with placebo (pooled, 40.7% vs 
31.7%, respectively; p<0.001).52 The durability of response 
to rifaximin was maintained for at least 3 months posttreat-
ment and differed significantly from placebo (p<0.001).52 
Rifaximin had a safety and tolerability profile comparable 
with that of placebo, with headache (6.1% vs 6.6%), upper 
respiratory tract infection (5.6% vs 6.2%), and abdominal 
pain (4.6% vs 5.5%) being the most commonly reported 
AEs.52 In addition, no patients reported C. difficile-associated 
diarrhea or ischemic colitis during these two trials.52
In an earlier randomized, double-blind, placebo-con-
trolled, investigator-initiated study that evaluated rifaximin 
400 mg tid for 10 days in patients with IBS (a lower dose of 
rifaximin given for a shorter duration than the indicated dos-
ing), rifaximin significantly improved global symptoms from 
baseline compared with placebo after 10 weeks of treatment-
free follow-up (36.4% vs 21.0%, respectively; p=0.02).54 
Based on the two phase III trials,52 the investigator-initiated 
trial,54 and two additional trials (one phase II55 and one single-
center56), the 2014 American College of Gastroenterology 
concluded that rifaximin was effective for the reduction of 
total symptoms of IBS and bloating in patients with IBS-D.9 
In that same year, the American Gastroenterological Associa-
tion provided a conditional recommendation for rifaximin for 
the treatment of IBS-D.57
The efficacy findings of the two pivotal studies52 of 
rifaximin were comparable with the data reported during 
a phase III repeat treatment study published in 2016.53 In 
that randomized, double-blind, placebo-controlled repeat 
treatment trial, patients with IBS-D who responded to a 
2-week course of open-label rifaximin (≥30% decrease from 
baseline in mean weekly pain score and ≥50% decrease 
from baseline in the frequency of mushy/watery stools dur-
ing ≥2 of the first 4 weeks posttreatment) and experienced 
symptom recurrence (<30% decrease in weekly mean 
abdominal pain score or <50% decrease from baseline in 
the frequency of mushy/watery stools) for ≥3 weeks dur-
ing a rolling 4-week consecutive period of the 18-week 
treatment-free observation phase were eligible for repeat 
treatment (Figure 1).53 Patients were randomly assigned to 
receive two repeat courses of rifaximin 550 mg or placebo 
tid for 14 days; the two double-blind courses were separated 
by 10 weeks.53 In the open-label treatment-free observation 
phase, 35.6% of 1074 patients with IBS-D who responded 
to a 2-week course of rifaximin reported no recurrence 
of symptoms (ie, up to 22 weeks posttreatment) and were 
not further evaluated.53 A significantly greater percentage 
of patients with recurrence who received the first repeat 
treatment course in the double-blind phase achieved the 
primary efficacy outcome of combined weekly response for 
abdominal pain and stool consistency during ≥2 of the first 
4 weeks after repeat treatment versus placebo (38.1% vs 
31.5%, respectively; p=0.03).53 Interestingly, patients who 
entered the double-blind repeat treatment phase (ie, after 
responding to a 2-week course of open-label rifaximin and 
subsequently experiencing recurrence) had significantly 
lower severity in individual symptom scores at double-blind 
baseline (prior to starting double-blind treatment) than 
what had been reported at the start of open-label treatment 
(p<0.001, for all comparisons), suggesting residual benefit 
from the first course of rifaximin therapy.53
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Rifaximin has been available for the last 30 years (in Italy 
since 1987 and in the USA since 2004), is currently marketed 
in more than 47 countries, and has a well-established safety 
and tolerability profile.58–60 A pooled safety analysis that 
included data from three randomized controlled studies (ie, 
one phase IIb and two phase III studies) of rifaximin for the 
treatment of nonconstipation IBS showed that rifaximin had 
a safety profile comparable with that of placebo (Table 3).61 
Furthermore, the repeat (up to three courses) treatment trial 
did not identify any new safety concerns.53 One patient in the 
repeat treatment trial developed C. difficile colitis 37 days 
after receiving 2-week repeat rifaximin treatment; however, 
this patient, who had a history of C. difficile infection, 
received a 10-day course of cefdinir as a treatment for a uri-
nary tract infection immediately preceding the development 
of C. difficile colitis.53
In a separate analysis, rifaximin was determined to be 
a safe and well-tolerated treatment for patients with IBS-
D, with a favorable “benefit-to-harm” ratio, particularly in 
Open-label treatment phase (N=2579) Double-blind repeat treatment phases (n=692)
Primary efficacy outcome
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31.5%
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Rifaximin
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Rifaximin
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7.1%
Placebo
11.7%
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41.2%
Rifaximin
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Rifaximin
46.6%
Abdominal pain
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56.8%
Stool consistency
responders
60.1%
Time to recurrence:
median, 10 weeks
2 weeks rifaximin
550 mg tid
18 weeks treatment-free
observation phase
4 weeks 
follow-up
Figure 1 Repeat treatment trial study design and efficacy outcomes.53
Notes: aSimultaneously meeting weekly response criteria for abdominal pain (≥30% decrease from baseline in mean weekly pain score) and stool consistency (≥50% decrease 
from baseline in number of days/week with Bristol Stool Scale type 6 or 7 stool) during ≥2 of the first 4 weeks posttreatment; bin patients with response to open-label 
rifaximin 4 weeks posttreatment, during the 18-week treatment-free observation phase; cp=0.03; dp=0.02; eDefined as the percentage of patients with response through the 
end of the first 6-week treatment-free observation phase and through the end of the second repeat treatment phase; fp=0.007; gDefined as adequate relief in both abdominal 
pain and stool consistency throughout the first double-blind repeat phase (through the 6-week treatment-free observation phase); hp=0.04; ipercentage of patients with 
improvement from baseline ≥1 point in weekly average bloating score for ≥2 of 4 weeks of primary evaluation period.
Abbreviations: EOS, end of study; tid, three times daily.
comparison with therapies that are administered daily, long 
term for IBS (eg, alosetron and tricyclic antidepressants; 
Table 4).62,63 Although rifaximin is administered as a 2-week 
course of therapy in IBS-D, rifaximin has a well-established 
safety and tolerability profile as daily, long-term adminis-
tration of 550 mg bid for the maintenance of remission of 
overt hepatic encephalopathy in patients with cirrhosis (ie, 
≥2 years; 510.5 person-years of exposure).64
Considerations for daily, long‑term 
versus short‑course therapy
The management of IBS includes both long-term and short-
term management strategies to help control symptoms. Most 
patients with IBS (89.6%) reported that they consider diet 
to cause and/or exacerbate GI symptoms, and most (91.9%) 
reported modifying their diet to try and decrease symptoms of 
IBS.65 However, some specialized diets (eg, low fermentable 
oligosaccharides, disaccharides, monosaccharides, and poly-
ols [FODMAP] and low gluten/gluten-free) may be difficult 
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for patients to maintain long term.9 Specific diets, including 
ones low in FODMAPs, are efficacious in improving symp-
toms of IBS; however, patients are advised to methodically 
and systematically reintroduce components of the previously 
restricted high FODMAP diet to determine the level of food 
restriction that is needed to maintain symptom control.66
A retrospective database analysis of any prescription 
type reported for patients receiving services from a large 
US-managed care organization (398,025 patients; 569,095 
prescriptions) indicated that the predicted probability of 
nonadherence to treatment was greater for chronic (ongoing; 
long-term) versus short-course (ie, acute) therapy (34% 
vs 17%, respectively).67 Further, questionnaire data from 
patients with GI disorders, including IBS, indicated that self-
reported adherence to treatment was inversely correlated to 
patient concerns regarding harm associated with treatment 
(r=−0.24; p<0.001).68 Adherence to treatment is impor-
tant, given that many of the options available for patients 
with IBS-D (Table 1) are ongoing, long-term (chronically 
administered) therapies1 and may also be associated with 
less desirable attributes and adverse effects.69
The benefit-to-risk profile of pharmacologic therapies for 
patients with IBS is an important consideration in guiding 
therapy. Certain pharmacologic agents (eg, eluxadoline and 
alosetron) used in the long term and indicated for the treat-
ment of patients with IBS-D require daily administration.70,71 
Eluxadoline treatment effects begin to diminish within 2–3 
weeks after drug discontinuation.72,73 Alosetron treatment 
effects diminish rapidly (within 1 week to 1 month) after 
drug discontinuation.74–76 Further, eluxadoline and alosetron 
have been associated with the occurrence of infrequent but 
serious AEs.71,73,77 It is important to note that, in response to 
safety concerns, such as the potential for the occurrence of 
the rare but serious AEs of ischemic colitis and constipation 
complications, alosetron is available in the USA under a risk 
evaluation and mitigation strategy program. However, an 
examination of 9 years of postmarketing data collected after 
inception of the risk management program showed that the 
incidence of ischemic colitis remained infrequent and stable, 
while complications of constipation decreased.77
In March 2017, the US Food and Drug Administration 
issued a safety communication warning that eluxadoline 
should not be administered to patients without a gallblad-
der because of the risk of developing serious pancreatitis 
that could result in hospitalization or mortality.78 From 
May 2015 through February 2017, the agency received 120 
reports of serious cases of pancreatitis or mortality. Among 
the 68 patients with available gallbladder status, 56 did 
not have a gallbladder and received the indicated dosage 
of eluxadoline;78 hence, eluxadoline is contraindicated in 
patients without a gallbladder.70 Furthermore, the eluxadoline 
prescribing information warns of a risk of sphincter of Oddi 
spasm, resulting in pancreatitis or hepatic enzyme elevation 
associated with acute abdominal pain.70 A 2017 pooled safety 
data analysis of one phase II and two phase III clinical stud-
ies reported that while uncommon, pancreatitis was the most 
common serious AE reported with eluxadoline; fortunately, 
pancreatitis resolved in all affected patients.79
Daily probiotics are commonly considered for managing 
GI conditions, but as noted previously, the most appropriate 
Table 3 Summary of safety of rifaximin 550 mg with 
nonconstipation IBSa
Patients with AEs Patients, n (%)
Rifaximin 550 mg
(n=1008)
Placebo
(n=829)
Any AE 529 (52.5) 436 (52.6)
Most common AEsb
Headache
Upper respiratory tract infection
Nausea
Abdominal pain
Diarrhea
Urinary tract infection
Nasopharyngitis
Sinusitis
Vomiting
Back pain
55 (5.5)
45 (4.5)
41 (4.1)
40 (4.0)
35 (3.5)
32 (3.2)
26 (2.6)
23 (2.3)
20 (2.0)
20 (2.0)
51 (6.2)
47 (5.7)
31 (3.7)
39 (4.7)
26 (3.1)
18 (2.2)
39 (4.7)
23 (2.8)
12 (1.4)
19 (2.3)
Drug-related AEs 124 (12.3) 89 (10.7)
Serious AEs
Any serious AE
Drug-related serious AEs
15 (1.5)
1 (0.1)
18 (2.2)
2 (0.2)
Discontinuations related to AEs 19 (1.9) 14 (1.7)
Notes: aPooled data from patients receiving rifaximin 550 mg bid for 2 or 4 weeks 
in a phase IIb clinical study or rifaximin 550 mg tid for 2 weeks in two phase III 
studies; bAEs reported in ≥2% of patients in either group. Adapted from Schoenfeld 
P, Pimentel M, Chang L, et al. Safety and tolerability of rifaximin for the treatment 
of irritable bowel syndrome without constipation: a pooled analysis of randomised, 
double-blind, placebo-controlled trials. Aliment Pharmacol Ther. 2014;39(10):1161–
1168. With permission from John Wiley and Sons.61
Abbreviations: AE, adverse event; bid, twice daily; IBS, irritable bowel syndrome; 
tid, three times daily.
Table 4 Benefit to harm evaluation of treatment for patients 
with IBS-Da,b
Treatment Number 
needed 
to treat
Number 
needed 
to harm
Number of patients 
benefiting for one 
patient harmedc
Alosetron 7.5 19.4 2.6
Tricyclic antidepressants 8 18.3 2.3
Rifaximin 10.6 8971 846
Notes: aEluxadoline data were not available at time study was conducted; bbased on 
discontinuation data due to an adverse event; cratio of the number needed to treat to 
the number needed to harm. Adapted from Am J Med, 125(4), Shah E, Kim S, Chong 
K, Lembo A, Pimentel M, Evaluation of harm in the pharmacotherapy of irritable 
bowel syndrome, 381–393, Copyright (2012), with permission from Elsevier,62 with 
additional data from Shah E, Pimentel M. Aliment Pharmacol Ther. 2014;39(9):973–983.63
Abbreviation: IBS-D, diarrhea-predominant irritable bowel syndrome.
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strain(s) to be used in managing symptoms of IBS, and at 
which dose, are currently unknown.9,80 Furthermore, evidence 
supporting the effectiveness of probiotics for the management 
of IBS symptoms is less robust than that for the treatment of 
other GI-related conditions (eg, pouchitis).81
Given the inherent disadvantages of therapies that require 
long-term administration, several short-course or as-needed 
therapies are administered for the management of IBS. Anti-
spasmodics (eg, dicyclomine) are efficacious for short-term 
relief of IBS symptoms, but results of a pooled analysis of 
15 clinical studies indicated an increased risk of AEs versus 
placebo (relative risk, 1.6; 95% CI, 1.1–2.4).9 Antispasmodics 
may in fact be administered as a long-term therapy, but are 
also administered as needed to manage individual symptoms. 
Although data on efficacy and safety in IBS are limited, fecal 
microbial transplant as short-course or as-needed therapy is 
currently considered an investigational treatment and is a 
complex procedure involving a donor and a patient.82
The efficacy of the nonsystemic agent rifaximin is favor-
able for the treatment of IBS-D compared with placebo in 
clinical studies,52,53 and the difference between the percent-
age of patients achieving response with rifaximin versus 
placebo (range, 7% to 10%) is consistent with the findings 
of an analysis of clinical trials for eluxadoline (range, 4% to 
13%), another therapy used for the treatment of IBS-D.73 In a 
clinical study of IBS-D treatment with alosetron, differences 
between three alosetron dosing regimens and placebo ranged 
from 12.2% to 20.1%.83 Further, the placebo effect has been 
established in patients with IBS, as data from a randomized, 
controlled study of patients administered open-label placebo 
showed that patients achieved a significant improvement in 
IBS symptoms and symptom severity compared with no 
treatment (p=0.002 and 0.03, respectively).84 The mechanism 
behind the placebo effect in IBS remains to be elucidated but 
may involve neurological and psychological aspects, includ-
ing patient expectations for symptom relief and conditioning, 
based on previous experiences with therapy, as well as the 
gut–brain axis.6,85
Rifaximin exhibits a favorable benefit-to-risk profile and 
is also administered as a short-course therapy for IBS-D. 
Given the well-known safety concerns regarding the effects 
of systemic antibiotics on the gut microbiota, health care pro-
viders may be concerned about the potential negative effect 
of nonsystemic rifaximin on the gut microbiota of patients 
with IBS-D. However, along with its favorable safety and 
tolerability profile, rifaximin has no apparent detrimental 
effects on gut microbiota and has not been associated with 
the emergence of clinically relevant bacterial antibiotic 
resistance in preclinical and clinical studies.86–89 Treatment 
with rifaximin 550 mg tid for 2 weeks did not alter the overall 
composition of the gut microbiota in patients with nonconsti-
pation IBS 4 weeks after the treatment ended.87 Further, repeat 
rifaximin treatment did not alter the composition of the gut 
microbiota in patients with IBS-D.87 Greater diversity in the 
gut microbiota was observed in patients with nonconstipation 
IBS after treatment with rifaximin, which steadily increased 
for up to 6 weeks after treatment; however, the increase from 
baseline in gut microbiota diversity did not achieve the level 
observed in the samples obtained from healthy individu-
als.87 Similarly, patients with IBS-D receiving up to three 
2-week courses of treatment with rifaximin in a randomized, 
double-blind, placebo-controlled trial experienced modest, 
transient changes in the relative abundance of multiple taxa 
of the fecal microbiota, including Peptostreptococcaceae and 
Clostridiaceae.90 Observed changes were generally reversed 
by the end of the study (46 weeks).90 Gut microbiota changes 
that are most relevant to explaining the clinical effectiveness 
of rifaximin in improving symptoms of IBS-D may be too 
subtle for current DNA-based methods or analytics to detect. 
The resistance of staphylococcal isolates to rifampicin was 
not observed after a 10-day course with rifaximin in rats;86 
similarly, in patients with IBS-D receiving up to three courses 
of a 2-week treatment with rifaximin in the repeat treatment 
study, skin swabs from multiple locations and stool samples 
showed no evidence of resistance of staphylococcal isolates to 
rifaximin, rifampin, or other clinically relevant antibiotics.88,89
Conclusion
IBS is a chronic, common GI disorder, and both long-term 
and short-course therapies are considered part of an overall 
management strategy. Modulation of the gut microbiota with 
agents (eg, antibiotics and probiotics) thought to correct gut 
dysbiosis that occurs in patients with IBS is one approach. 
Data demonstrate that short-course (ie, 2-week) therapy with 
the nonsystemic antibiotic rifaximin is safe and efficacious 
for the treatment of IBS-D. Unless there is a contraindication 
to using a 2-week course of rifaximin, the literature suggests 
that it would be a reasonable first-line treatment choice for 
IBS-D, given the response rate and the durability of response, 
as well as its benefit-to-risk profile and lack of associated 
clinically significant bacterial antibiotic resistance. 
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